Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lineage Cell Therapeutics | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 626.42M | -6.7x | 2.24 | ILA 321.60 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Compugen | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 563.65M | -15.8x | -0.22 | ILA 625.70 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Batm | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 377.53M | -229.8x | 1.53 | ILA 90.40 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Oramed Pharma | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 361.15M | 4.6x | 0.02 | ILA 870 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
BioLine RX | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 159.58M | -1.2x | -0.04 | ILA 13.30 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Bonus Biogroup | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 143.65M | -5.1x | ILA 12.30 | -4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Enlivex | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 119.83M | -1.3x | -0.08 | ILA 568 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
DNA Group TR | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 108.51M | 7.2x | 0.02 | ILA 88.10 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Pluri Inc | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 95.37M | -1.2x | -0.03 | ILA 1,837 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
XTL Bio | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 93.03M | -19.9x | -0.88 | ILA 7.60 | -9.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Matricelf | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 61.11M | ILA 377 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Evogene | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 56.19M | -0.7x | -0.02 | ILA 995 | 8.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Kadimastem Ltd | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 35.97M | -20.3x | -0.04 | ILA 857.70 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Purple Biotech | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 27.25M | -0.3x | -0.01 | ILA 7.80 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Nextage Therapeutics | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 20.72M | ILA 61.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Merchavia | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 11.56M | -1.2x | -0.33 | ILA 68.80 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Univo Pharma | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 2.84M | ILA 93,000 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||||
Hadasit Bio | Tel Aviv | Healthcare | Biotechnology & Medical Research | ILS 2.83M | -0.4x | -0.01 | ILA 25.50 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |